Longevity comparison tables

Figures and tables to reuse

Choose a topic. Download a figure, its caption and the underlying rows.

GLP-1 products and trial candidates

Six selected formulations and candidates, not the complete GLP-1 pipeline. US label information and sponsor trial reports are different source types. This is not an efficacy comparison or prescribing guide.

PNG figure SVG figure Caption + sourcesCSV tableJSON data

Preview: GLP-1 products and trial candidates

Read table: GLP-1 products and trial candidates

GLP-1 products and trial candidates

Product / molecule	Form in the source	US label or trial status
Wegovy injection · semaglutide	Weekly injection	US-labelled formulation
Wegovy pill · semaglutide	Daily tablet	US-labelled formulation
Zepbound · tirzepatide	Weekly injection	US-labelled formulation
Foundayo · orforglipron	Daily pill	FDA approval: 1 April 2026
Retatrutide	Weekly injection in trials	Investigational; not an FDA-approved drug
CagriSema	Weekly injection in trials	Phase 3 sponsor report; not a product label

Source 1 · Source 2 · Source 3 · Source 4 · Source 5 · Source 6 · Read the explanation

Wolverine, GLOW and KLOW: reported ingredients

Names as defined by KLOW Clinic; sellers may use different formulations. Ingredient lists do not establish the effectiveness or safety of a combination.

PNG figure SVG figure Caption + sourcesCSV tableJSON data

Preview: Wolverine, GLOW and KLOW: reported ingredients

Read table: Wolverine, GLOW and KLOW: reported ingredients

Wolverine, GLOW and KLOW: reported ingredients

Reported name	Listed ingredients
Wolverine	BPC-157 + TB-500
GLOW	BPC-157 + TB-500 + GHK-Cu
KLOW	BPC-157 + TB-500 + GHK-Cu + KPV

Source 1 · Read the explanation

Biological-age methods: inputs and outputs

Four selected methods, not a ranking. An age estimate and a pace-of-aging measure are different outputs; these rows are not interchangeable test results.

PNG figure SVG figure Caption + sourcesCSV tableJSON data

Preview: Biological-age methods: inputs and outputs

Read table: Biological-age methods: inputs and outputs

Biological-age methods: inputs and outputs

Method	Inputs	What the model estimates
Clinical Phenotypic Age	Nine clinical biomarkers plus chronological age	A mortality-risk-based age estimate, in years
DNAm PhenoAge	DNA methylation at 513 sites	A methylation estimate of Phenotypic Age
Original Horvath clock	DNA methylation at 353 sites	Age from a model trained on chronological age
DunedinPACE	Blood DNA methylation at 173 sites	Pace of aging, not age in years

Source 1 · Source 2 · Source 3 · Read the explanation

Creatine during GLP-1 treatment: trial design

NCT07625202: a registered trial design, not a treatment result. The estimated enrolment is not the number of participants who completed the trial.

PNG figure SVG figure Caption + sourcesCSV tableJSON data

Preview: Creatine during GLP-1 treatment: trial design

Read table: Creatine during GLP-1 treatment: trial design

Creatine during GLP-1 treatment: trial design

Field	Retrieved record
Participants	40 estimated
Status	Recruiting
Comparison	Creatine vs placebo; resistance training
Primary outcome	Sit-to-stand performance, 12 weeks
Lean tissue	Secondary DXA outcome, 12 weeks
Posted results	None in the retrieved record

Source 1 · Read the explanation

Methods, reuse and update history

Figures reproduce selected, source-linked tables already reviewed by StemCellAtlas. The GLP-1 table selects name, form and status from the reviewed comparison tool. No source records were altered and no new clinical results were added.

You may reuse these StemCellAtlas-created figures and captions with source attribution. This permission does not cover the underlying papers, registry records or third-party works. Keep the snapshot date and scope note when quoting a figure.

30 August 2026 · version 2026-08-30.1

First figure pack: four figures, source captions and a six-entry GLP-1 export. The three other tables were already available. Figures use the existing 30 August source snapshot; this is a packaging release, not new research.

Figure metadata JSON · Update history JSON

What is in this collection?

Thirteen selected comparison tables, each linked to its source records and explanatory article. Download rows retain the snapshot date, article URL and source URLs. They are not a complete literature review or a clinical database.

How the tables were made

Source documents were captured on 30 August 2026. Relevant fields and study details were extracted, checked and paraphrased. Study-specific numbers remain separate; missing values are described as missing rather than replaced with zero. This is AI-assisted editorial work, not new clinical research.

Attribution and reuse

Cite the original sources as well as the relevant StemCellAtlas comparison when reusing a table. Underlying paper and registry rights remain with their respective owners; these downloads do not grant rights to reproduce the underlying works. Source links open current records, which may differ from the snapshot.

ClinicalTrials.gov-derived entries retain the NCT number, the registry’s own update date and our extraction date in JSON and CSV. NCT07625202 was updated on 4 June 2026; NCT05929066 on 21 August 2026. We select and relabel fields for comparison, without modifying the registry record.

• Orforglipron vs oral semaglutide — CSV · JSON
• Retatrutide vs tirzepatide — CSV · JSON
• GLP-1 weight loss and muscle — CSV · JSON
• Creatine with GLP-1: the trial — CSV · JSON
• Vitamins during GLP-1 treatment — CSV · JSON
• GLP-1 treatment and hair shedding — CSV · JSON
• What is the Wolverine stack? — CSV · JSON
• GLOW vs KLOW peptide stacks — CSV · JSON
• GHK-Cu: topical vs injection — CSV · JSON
• NMN vs NR: human research — CSV · JSON
• NAD IV vs oral supplements — CSV · JSON
• Biological-age tests compared — CSV · JSON
• What is Bryan Johnson’s protocol? — CSV · JSON